First-person stories can help people with Crohn’s disease feel less alone and show ways to turn a diagnosis into advocacy or research involvement. The article highlights pediatric-to-adult transition issues and patient...

Predicting early need for infliximab could help identify children with Crohn’s disease who may benefit from earlier biologic therapy instead of prolonged conventional treatment. A reliable prediction tool may shorten...

The study identifies ABCA1 deficiency and epithelial cholesterol accumulation as drivers of colonic injury and inflammation in a hamster model, highlighting a possible new mechanism relevant to IBD pathogenesis. That...

IL-11 is implicated in fibrostenotic Crohn’s disease; determining whether it is a reversible therapeutic target could lead to treatments that prevent or reverse strictures rather than only managing inflammation or...

Patients with IBD have an increased colorectal cancer risk, and those with PSC, extensive colitis, severe inflammation, or prior dysplasia are at especially high risk. High-quality surveillance techniques can improve...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Remission, and Research and clinical trials. The original article is from Inflammatory Bowel Diseases.

Based on the title and source metadata, this appears to be a conference abstract related to Crohn's disease, Inflammatory bowel disease, and Microbiome. The original article is from Anais do XI Congresso Médico...

Real-world data on upadacitinib help patients and clinicians understand how the drug performs outside clinical trials, including how long patients stay on treatment, remission rates, and common side effects.

The report suggests fertility treatments—particularly embryo transfer/IVF—can be successful for many women with Crohn's disease or ulcerative colitis, which may reassure patients concerned about fertility after IBD or...

Fatigue affects a large share of people with IBD and often persists despite remission; understanding treatment options and the need for a broad care plan can help patients and clinicians set realistic goals and...

The paper suggests a new animal model linking syndromic albinism mutations, intestinal inflammation, and gut-microbiome changes—areas relevant to understanding IBD biology and potential microbiome-targeted interventions.

This study identifies PLA2G2A as a drug target in experimental colitis and reports that AAIVa—an herbal-derived compound—reduced inflammation and disease measures in a mouse model, which could point to new therapeutic...

The study identifies thymoquinone as a compound that reduced inflammation and protected the intestinal barrier in a mouse colitis model, highlighting a possible new avenue for IBD drug discovery focused on the Notch...

This story highlights fundraising and awareness activities for the Crohn’s & Colitis Foundation, showing how public figures with IBD can help raise funds and visibility for the community.

The study provides first human evidence that a single colonoscopic FMT can eradicate mucosal adherent-invasive E. coli (AIEC), a bacterium linked to Crohn’s disease, and it shows associated shifts in mucosal microbiota...

Fundraising events support research, education, advocacy, and direct patient services that can benefit people living with Crohn’s disease and other forms of IBD. A public figure with lived experience being honored can...

This preclinical work suggests the gut microbiota and tryptophan-derived metabolites that activate AhR may be important in reducing colitis-related inflammation — a potential route for future therapies relevant to...

Company-reported one-year results suggest mirikizumab (Omvoh), an IL-23p19 inhibitor, can achieve multi-dimensional treatment goals including symptom control, quality-of-life improvement, and steroid-free deep remission...

Support organizations can offer education, peer connection, mental-health services, advocacy, and programs for children and families that complement medical care. Knowing where to find these resources can help people...

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Ct Enterography. The original article is from idp.springer.com.

Deep remission is an emerging treatment target in Crohn’s disease that combines symptoms and objective measures. A meaningful proportion of patients in VIVID-1 achieved corticosteroid-free deep remission with mirikizumab...

An oral IL-23 blocker showed benefit in a Phase IIb trial for moderate-to-severe ulcerative colitis, which could add a new pill option for patients—especially those who’ve failed injectable biologics.

Cure8 found this source from streetinsider.com, but the page could not be read reliably yet. It is tagged for Mirikizumab, IL-23 inhibitor, and Research and clinical trials. Open the original article for the full...

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Diet and lifestyle. Open the original article for the full details.

Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Mirikizumab, IL-23 inhibitor, and Research and clinical trials.

Cure8 found this source from fiercepharma.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, Mirikizumab, and IL-23 inhibitor. Open the original article for the full details.

The article reports Phase 3 post‑hoc analyses showing that mirikizumab (Omvoh) produced higher rates of composite, multidimensional remission measures in UC and Crohn’s disease versus placebo, which could matter to...

Phase 3 results suggest mirikizumab (Omvoh) can produce sustained, steroid-free remission-related outcomes at one year in both ulcerative colitis and Crohn’s disease, including in some patients who previously failed...

Cure8 could only read part of this source from benzinga.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis and Research and clinical trials.

The study suggests a dietary protein (ovotransferrin) can reduce colitis severity in mice by changing the gut microbiota and increasing certain secondary bile acids that lower inflammation and gut permeability.

New one-year trial analyses suggest mirikizumab (Omvoh) may help more people with moderate-to-severe ulcerative colitis or Crohn’s disease reach combined clinical and endoscopic goals and reduce steroid dependence.

These results suggest mirikizumab can achieve multiple treatment goals at once — symptoms, objective inflammation measures, and steroid-free status — outcomes that matter to people with IBD because they reflect both...

This study connects USP25 to NOD2–XIAP signaling and Crohn’s disease genetics, suggesting a possible target for future therapies or biomarkers relevant to IBD pathogenesis.

Capsaicin is commonly consumed and acts on TRPV1, which is increased in inflamed IBD tissue; depending on dose and disease activity it may help or worsen inflammation and symptom-related pain.

MMP-2 regulates tissue remodeling and inflammation in IBD; targeting it might help prevent barrier damage, chronic inflammation, or fibrosis but requires selective approaches to avoid harming normal repair processes.

Based on the title and source metadata, this appears to be a case report related to Crohn's disease and Research and clinical trials. The original article is from Updates in surgery.

The paper suggests a specific gut bacterium and its metabolite can protect against intestinal inflammation in mice by acting on enteric neurons, revealing a new neuro-immune pathway that could inform future IBD...

This study explores a non-drug dietary supplement approach aimed at changing host–microbiome interactions after surgery — a potentially relevant prevention strategy for postoperative Crohn's disease recurrence if later...

A phase 2 trial testing an oral integrin α4β7 inhibitor could matter because it explores a potential new mechanism for treating moderately to severely active ulcerative colitis, including patients who have failed other...

This registry-based study compares early control of inflammation on conventional therapy versus escalating to advanced treatments in newly diagnosed ulcerative colitis, using CRP and fecal calprotectin to define...

Findings highlight cultivable gut microbiota differences in Crohn’s disease versus controls and present preliminary in vitro antimicrobial activity of two thyme essential oils—topics that may interest patients following...

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Mental health and quality of life. The original article is from BMC Gastroenterology.

Microbiota-derived metabolites are linked to inflammation and gut barrier function, so they could become biomarkers or therapeutic targets for Crohn’s disease and ulcerative colitis. Patients may see future tests or...

This research links a gut bacterial metabolite to modulation of an immune receptor (GPR183) that is elevated in colon/rectum of ulcerative colitis patients, suggesting a possible microbiota‑to‑immune pathway relevant to...

Findings suggest GM-CSF signaling may help limit epithelial injury and shape immune cell states in Crohn’s disease, which could be relevant to understanding inflammation and future therapies targeting innate immunity or...

Many people with Crohn’s disease or ulcerative colitis use biologic drugs; new clinical and real-world data about a subcutaneous infliximab option could affect treatment choice, switching decisions, and practical use in...

The review links ER stress and mitochondrial dysfunction to core IBD processes (inflammation, barrier damage, cell death) and highlights MERCs as an integrated signaling hub, suggesting new biomarker and therapeutic...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis and Pediatrics and family. The original article is from BMC Infectious Diseases.